Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

This is a single-center, single-arm, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib as adjuvant therapy in hepatocellular carcinoma (HCC) participants who are at high risk of recurrence after curative resection.

Trial Details

NCT ID

NCT06454578

Phase

PHASE2

Sponsor

Qilu Hospital of Shandong University

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

Adebrelimab + Apatinib

Locations (sample)

Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

Participants must meet all of the following conditions in order to be enrolled in this study:
Voluntarily participate in this study and sign an informed consent form.
Participants diagnosed with HCC through pathological histology/cytology or clinically diagnosed with HCC according to the Diagnosis and Treatment G…
Within 4-12 weeks prior to enrollment, radical resection surgery was performed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →